Most large employers hold steady on GLP-1 coverage, for now

A new survey indicates most large employers are maintaining coverage for GLP-1 obesity drugs like Wegovy and Zepbound in 2026, but many are evaluating restrictions or dropping coverage for 2027 due to high costs. This creates uncertainty for practices managing patients on these medications. The decision timeline means patients may face new prior authorization hurdles or lose coverage in the next plan year. Begin conversations with patients now about potential 2027 coverage changes and document medical necessity rigorously for current auth requests.